Andrews, J. A., Babu, S., Benatar, M., McDermott, C., Cochrane, T., Chary, S., Chew, S., Zhu, H., Wu, F., ... VALOR and OLE Working Group. (2022). Trial of antisense oligonucleotide tofers for SOD1 ALS. *New England Journal of Medicine*, **387**, 1099–1110. https://doi.org/10.1056/NEJMoa2204705

Morgan, B. P., & Harris, C. L. (2015). Complement, a target for therapy in inflammatory and degenerative diseases. *Nature Reviews. Drug Discovery*, **14**, 857–877. https://doi.org/10.1038/nrd4657

Najjar-Debbiny, R., Gronich, N., Weber, G., Khoury, J., Amar, M., Stein, N., Goldstein, L. H., & Saliba, W. (2023). Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. *Clinical Infectious Diseases*, **76**, e342–e349. https://doi.org/10.1093/cid/ciac443

Oh, S. T., Talpaz, M., Gerds, A. T., Gupta, V., Verstovsek, S., Mesa, R., Miller, C. B., Rivera, C. E., Fleischman, A. G., Goel, S., Heaney, M. L., O'Connell, C., Arcasoy, M. O., Zhang, Y., Kawashima, J., Ganz, T., Kowalski, M., & Brachmann, C. B. (2020). ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. *Blood Advances*, **4**, 4282–4291. https://doi.org/10.1182/bloodadvances.2020002662

Osborne, C. K., Wakeling, A., & Nicholson, R. I. (2004). Fulvestrant: An oestrogen receptor antagonist with a novel mechanism of action. *British Journal of Cancer*, **90**, S2-S6. https://doi.org/10.1038/sj.bjc.6601629

Ozelo, M. C., Mahlangu, J., Pasi, K. J., Giermasz, A., Leavitt, A. D., Laffan, M., Symington, E., Quon, D. V., Wang, J. D., Peerlinck, K., Pipe, S. W., Madan, B., Key, N. S., Pierce, G. F., O'Mahony, B., Kaczmarek, R., Henshaw, J., Lawal, A., Jayaram, K., ... GENER8-1 Trial Group. (2022). Valoctocogene roxaparvovec gene therapy for hemophilia A. *New England Journal of Medicine*, **386**, 1013–1025. https://doi.org/10.1056/NEJMoa2113708

Packer, M. (2023). Mechanistic and clinical comparison of the erythropoietic effects of SGLT2 inhibitors and prolyl hydroxylase inhibitors in patients with chronic kidney disease and renal anemia. *American Journal of Nephrology*, **1–5**. https://doi.org/10.1159/000531084

Papi, A., Ison, M. G., Langley, J. M., Lee, D.-G., Leroux-Roels, I., Martinon-Torres, F., Schwarz, T. F., van Zyl-Smit, R. N., Campora, L., Dezutter, N., de Schrevel, N., Fissette, L., David, M. P., van der Wielen, M., Kostanyan, L., & Hulstrøm, V. (2023). Respiratory syncytial virus prefusion F protein vaccine in older adults. *New England Journal of Medicine*, **388**, 595–608. https://doi.org/10.1056/NEJMoa2209604

Patel, S. S., Lally, D. R., Hsu, J., Wykoff, C. C., Eichenbaum, D., Heier, J. S., Jaffe, G. J., Westby, K., Desai, D., Zhu, L., & Khanani, A. M. (2023). Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. *Eye*, **37**, 3551–3557. https://doi.org/10.1038/s41433-023-02497-w

Ramírez-Marín, H. A., & Tosti, A. (2022). Evaluating the therapeutic potential of ritlecitinib for the treatment of alopecia areata. *Drug Design, Development and Therapy*, **16**, 363–374. https://doi.org/10.2147/DDDT.S334727

Reich, K., Papp, K. A., Blauvelt, A., Langley, R. G., Armstrong, A., Warren, R. B., Gordon, K. B., Merola, J. F., Okubo, Y., Madden, C., Wang, M., Cioffi, C., Vanvoorden, V., & Lebwohl, M. (2021). Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): Efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. *Lancet*, **397**, 487–498. https://doi.org/10.1016/S0140-6736(21)00125-2

Richards, D., Gever, J. R., Ford, A. P., & Fountain, S. J. (2019). Action of MK-7264 (gefapaxant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation. *British Journal of Pharmacology*, **176**, 2279–2291. https://doi.org/10.1111/bph.14677

Ritchlin, C. T., Coates, L. C., McInnes, I. B., Mease, P. J., Merola, J. F., Tanaka, Y., Asahina, A., Gossec, L., Gottlieb, A. B., Warren, R. B.,

Ink, B., Bajracharya, R., Shende, V., Coarse, J., & Landewé, R. B. M. (2023). Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. *Annals of the Rheumatic Diseases*, **82**, 1404–1414. https://doi.org/10.1136/ard-2023-224431

Robinson, M. F., Damjanov, N., Stamenkovic, B., Radunovic, G., Kivitz, A., Cox, L., Manukyan, Z., Banfield, C., Saunders, M., Chandra, D., Vincent, M. S., Mancuso, J., Peeva, E., & Beebe, J. S. (2020). Efficacy and safety of PF-06651600 (ritlecitinib), a novel JAK3/TEC inhibitor, in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate. *Arthritis & Rheumatology*, **72**, 1621–1631. https://doi.org/10.1002/art.41316

Rovin, B. H., Barratt, J., Heerspink, H. J. L., Alpers, C. E., Bieler, S., Chae, D. W., Diva, U. A., Floege, J., Gesualdo, L., Inrig, J. K., Kohan, D. E., Komers, R., Kooienga, L. A., Lafayette, R., Maes, B., Mafecki, R., Mercer, A., Noronha, I. L., Oh, S. W., ... Zizzi, C. F. (2023). Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. *Lancet*, **402**, 2077–2090. https://doi.org/10.1016/S0140-6736(23)02302-4

Sarnak, M. J., Agarwal, R., Boudville, N., Chowdhury, P. C. P., Eckardt, K. U., Gonzalez, C. R., Kooienga, L. A., Koury, M. J., Ntoso, K. A., Luo, W., Parfrey, P. S., Vargo, D. L., Winkelmayer, W. C., Zhang, Z., & Chertow, G. M. (2023). Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis. *Nephrology, Dialysis, Transplantation*, **38**, 2358–2367. https://doi.org/10.1093/ndt/gfad074

Singh, A. K., Cizman, B., Carroll, K., McMurray, J. J. V., Perkovic, V., Jha, V., Johansen, K. L., Lopes, R. D., Macdougall, I. C., Obrador, G. T., Waikar, S. S., Wanner, C., Wheeler, D. C., Wiecek, A., Stankus, N., Strutz, F., Blackorby, A., Cobitz, A. R., Meadowcroft, A. M., ... Solomon, S. (2022). Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients: A randomized clinical trial. *JAMA Internal Medicine*, **182**, 592–602. https://doi.org/10.1001/jamainternmed.2022.0605

Stearns, V., Ullmer, L., López, J. F., Smith, Y., Isaacs, C., & Hayes, D. (2002). Hot flushes. *Lancet*, **360**, 1851–1861. https://doi.org/10.1016/S0140-6736(02)11774-0

Strober, B., Paul, C., Blauvelt, A., Thaçi, D., Puig, L., Lebwohl, M., White, K., Vanvoorden, V., Deherder, D., Gomez, N. N., & Eyerich, K. (2023). Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. *Journal of the American Academy of Dermatology*, **89**, 486–495. https://doi.org/10.1016/j.jaad.2023.04.063

Turner, N. C., Oliveira, M., Howell, S. J., Dalenc, F., Cortes, J., Gomez Moreno, H. L., Hu, X., Jhaveri, K., Krivorotko, P., Loibl, S., Morales Murillo, S., Okera, M., Park, Y. H., Sohn, J., Toi, M., Tokunaga, E., Yousef, S., Zhukova, L., de Bruin, E. C., ... CAPItello-291 Study Group. (2023). Capivasertib in hormone receptor-positive advanced breast cancer. *New England Journal of Medicine*, **388**, 2058–2070. https://doi.org/10.1056/NEJMoa2214131

Verstovsek, S., Gerds, A. T., Vannucchi, A. M., al-Ali, H. K., Lavie, D., Kuykendall, A. T., Grosicki, S., Iurlo, A., Goh, Y. T., Lazaroiu, M. C., Egyed, M., Fox, M. L., McLornan, D., Perkins, A., Yoon, S. S., Gupta, V., Kiladjian, J. J., Granacher, N., Lee, S. E., ... Yoon, S. S. (2023). Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): Results from an international, double-blind, randomised, controlled, phase 3 study. *Lancet*, **401**, 269–280. https://doi.org/10.1016/S0140-6736(22)02036-0

Walsh, E. E., Pérez Marc, G., Zareba, A. M., Falsey, A. R., Jiang, Q., Patton, M., Polack, F. P., Llapur, C., Doreski, P. A., Ilangovan, K., Rämet, M., Fukushima, Y., Hussen, N., Bont, L. J., Cardona, J., DeHaan, E., Castillo Villa, G., Ingilizova, M., Eiras, D., ... RENOIR
<figure><img src="image_24.png" /></figure>

Clinical Trial Group. (2023). Efficacy and safety of a bivalent RSV pre-fusion F vaccine in older adults. *The New England Journal of Medicine*, **388**, 1465-1477. https://doi.org/10.1056/NEJMoa2213836

Yun, M. R., Kim, D. H., Kim, S. Y., Joo, H. S., Lee, Y. W., Choi, H. M., Park, C. W., Heo, S. G., Kang, H. N., Lee, S. S., Schoenfeld, A. J., Drilon, A., Kang, S. G., Shim, H. S., Hong, M. H., Cui, J. J., Kim, H. R., & Cho, B. C. (2020). Repotrectinib exhibits potent antitumor activity in treatment-naïve and solvent-front-mutant ROS1-rearranged non-small cell lung cancer. *Clinical Cancer Research*, **26**, 3287-3295. https://doi.org/10.1158/1078-0432.CCR-19-2777

Zaidman, C. M., Proud, C. M., McDonald, C. M., Lehman, K. J., Goedeker, N. L., Mason, S., Murphy, A. P., Guridi, M., Wang, S., Reid, C., Darton, E., Wandel, C., Lewis, S., Malhotra, J., Griffin, D. A., Potter, R. A., Rodino-Klapac, L. R., & Mendell, J. R. (2023). Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged ≥4 to <8 years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR). *Annals of Neurology*, **94**, 955-968. https://doi.org/10.1002/ana.26755

Zhang, H., Rizk, D. V., Perkovic, V., Maes, B., Kashihara, N., Rovin, B., Trimarchi, H., Sprangers, B., Meier, M., Kollins, D., Papachristofi, O., Milojevic, J., Junge, G., Nidamarthy, P. K., Charney, A., & Barratt, J. (2024). Results of a randomized double-blind placebo-controlled phase

2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. *Kidney International*, **105**, 189-199. https://doi.org/10.1016/j.kint.2023.09.027

## SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Papapetropoulos, A., Topouzis, S., Alexander, S. P. H., Cortese-Krott, M., Kendall, D. A., Martemyanov, K. A., Mauro, C., Nagercoil, N., Panettieri, R. A. Jr, Patel, H. H., Schulz, R., Stefanska, B., Stephens, G. J., Teixeira, M. M., Vergnolle, N., Wang, X., & Ferdinandy, P. (2024). Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review. *British Journal of Pharmacology*, **1-23**. https://doi.org/10.1111/bph.16337
<figure><img src="image_23.png" /></figure>

Clinical Trial Group. (2023). Efficacy and safety of a bivalent RSV pre-fusion F vaccine in older adults. *The New England Journal of Medicine*, **388**, 1465-1477. https://doi.org/10.1056/NEJMoa2213836

Yun, M. R., Kim, D. H., Kim, S. Y., Joo, H. S., Lee, Y. W., Choi, H. M., Park, C. W., Heo, S. G., Kang, H. N., Lee, S. S., Schoenfeld, A. J., Drilon, A., Kang, S. G., Shim, H. S., Hong, M. H., Cui, J. J., Kim, H. R., & Cho, B. C. (2020). Repotrectinib exhibits potent antitumor activity in treatment-naïve and solvent-front-mutant ROS1-rearranged non-small cell lung cancer. *Clinical Cancer Research*, **26**, 3287-3295. https://doi.org/10.1158/1078-0432.CCR-19-2777

Zaidman, C. M., Proud, C. M., McDonald, C. M., Lehman, K. J., Goedeker, N. L., Mason, S., Murphy, A. P., Guridi, M., Wang, S., Reid, C., Darton, E., Wandel, C., Lewis, S., Malhotra, J., Griffin, D. A., Potter, R. A., Rodino-Klapac, L. R., & Mendell, J. R. (2023). Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged ≥4 to <8 years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR). *Annals of Neurology*, **94**, 955-968. https://doi.org/10.1002/ana.26755

Zhang, H., Rizk, D. V., Perkovic, V., Maes, B., Kashihara, N., Rovin, B., Trimarchi, H., Sprangers, B., Meier, M., Kollins, D., Papachristofi, O., Milojevic, J., Junge, G., Nidamarthy, P. K., Charney, A., & Barratt, J. (2024). Results of a randomized double-blind placebo-controlled phase

2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. *Kidney International*, **105**, 189-199. https://doi.org/10.1016/j.kint.2023.09.027

## SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Papapetropoulos, A., Topouzis, S., Alexander, S. P. H., Cortese-Krott, M., Kendall, D. A., Martemyanov, K. A., Mauro, C., Nagercoil, N., Panettieri, R. A. Jr, Patel, H. H., Schulz, R., Stefanska, B., Stephens, G. J., Teixeira, M. M., Vergnolle, N., Wang, X., & Ferdinandy, P. (2024). Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review. *British Journal of Pharmacology*, **1-23**. https://doi.org/10.1111/bph.16337